Categories: HealthcareNews

CONMED Corporation to Announce Third Quarter 2025 Financial Results on November 5, 2025

LARGO, Fla.–(BUSINESS WIRE)–CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2025 after the market close on Wednesday, November 5, 2025. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.


To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED’s website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company’s Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Contacts

CONMED Corporation

Todd W. Garner

Chief Financial Officer
ToddGarner@conmed.com

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

12 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

12 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

12 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

12 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

12 hours ago